AXGN:NASDAQ
AxoGen, Inc Common Stock
$44.35
arrow_downward
-1.92%(-0.87) 1D
$44.30
arrow_downward
-0.11% (-0.050)bedtimeAfter hours
Closed: Aug 6, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$45.07
High
$45.62
Low
$44.11
Mkt. cap
2.38B
Avg. vol.
0.00
Volume
550.94K
52-wk high
$46.95
52-wk low
$13.50
EPS
-$0.68
Beta
1.11
Shares outstanding
53.76M
No. of employees
622
Open
$45.07
High
$45.62
Low
$44.11
Mkt. cap
2.38B
Avg. vol.
0.00
Volume
550.94K
52-wk high
$46.95
52-wk low
$13.50
EPS
-$0.68
Beta
1.11
Shares outstanding
53.76M
No. of employees
622
News stories
From sources across the web
https://www.dars.gov.et/
·
2 months ago
Axogen Inc. (AXGN) Q1 2026 Earnings: EPS Falls Slightly Short Amid Lower Stock Reaction - Earnings Analysis
https://www.dars.gov.et/
·
2 months ago
Axogen Q1 2026 Earnings: EPS Misses Estimates; Shares Slide on Slight Miss - Surprise Factor Analysis
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com
AI content may include mistakes. Learn more